

PRMT5 protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/PB369E019AD3EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PB369E019AD3EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "PRMT5 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in PRMT5 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

PRMT5 protein inhibitors Understanding

PRMT5 protein inhibitors: Overview

Protein arginine methyltransferase 5 (PRMT5) is a critical regulatory protein linked to genome organization, cell cycle regulation, and stem cell differentiation¹. It forms an active complex with MEP50 and transfers methyl groups from S-adenosylmethoinine (SAM) to histone proteins, transcription factors, and other regulatory proteins. These methylations form mono and symmetrically di-methylated arginine residues.

Dysregulation of PRMT5 activity is associated with many cancers including lymphomas, lung cancer, and breast cancer. Additionally, PRMT5 is linked to kidney disease, heart disease, and neurological disorders including Huntington's and Alzheimer's. Recent scientific breakthroughs have caused PRMT5 to emerge as a promising new drug target. New findings in both the specific inhibition of PRMT5 and in metabolic pathways

linked to its activity have brought new attention to this important protein.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PRMT5 protein inhibitors R&D. The therapies under development are focused on novel approaches for PRMT5 protein inhibitors.

PRMT5 protein inhibitors Emerging Drugs Chapters

This segment of the PRMT5 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PRMT5 protein inhibitors Emerging Drugs

PRT811: Prelude Therapeutics

PRT811, Prelude's second clinical product candidate, is an oral PRMT5 inhibitor under development for patients with PRMT5-dependent cancers, including central nervous system (CNS) tumors such as glioblastoma multiforme (GBM) and primary CNS lymphoma. PRT811 is designed to have high potency and selectivity and optimized brain exposure. PRT811 is being studied in a Phase 1 clinical trial in solid tumors, including GBM and primary central nervous system lymphomas (PCNSL).

Pemrametostat: GlaxoSmithKline

Pemrametostat (formerly GSK 3326595) is an oral inhibitor of protein arginine methyltransferase 5 (PRMT 5), being developed by GlaxoSmithKline. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin's Lymphoma and solid tumors.

Further product details are provided in the report.....

PRMT5 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PRMT5 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on PRMT5 protein inhibitors

There are approx. 9+ key companies which are developing the PRMT5 protein inhibitors. The companies which have their PRMT5 protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, GlaxoSmithKline.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

PRMT5 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PRMT5 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PRMT5 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PRMT5 protein inhibitors drugs.

PRMT5 protein inhibitors Report Insights

- PRMT5 protein inhibitors Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

PRMT5 protein inhibitors Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing PRMT5 protein inhibitors drugs?

How many PRMT5 protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PRMT5 protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PRMT5 protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for PRMT5 protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Prelude Therapeutics

GlaxoSmithKline

Pfizer

Amgen

Mirati Therapeutics

Jubilant Biosys

Agios Pharmaceuticals

Tango Therapeutics

Lead Pharma

Argonaut Therapeutics

Key Products

PRT811

Pemrametostat

AMG 193

PRT 543

PF 06939999

MRTX 1719

MRTX 4646

JPRMT 5i

AT101

TNG908

JBI 778

Contents

Introduction

Executive Summary

PRMT5 protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

PRMT5 protein inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Pemrametostat: GlaxoSmithKline

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

PRT811: Prelude Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
AMG 193: Amgen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
PRMT5 protein inhibitors Key Companies
PRMT5 protein inhibitors Key Products
PRMT5 protein inhibitors- Unmet Needs
PRMT5 protein inhibitors- Market Drivers and Barriers
PRMT5 protein inhibitors- Future Perspectives and Conclusion
PRMT5 protein inhibitors Analyst Views
PRMT5 protein inhibitors Key Companies
Appendix

I would like to order

Product name: PRMT5 protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PB369E019AD3EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB369E019AD3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970